<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01912469</url>
  </required_header>
  <id_info>
    <org_study_id>TEIR-2</org_study_id>
    <secondary_id>2009-010898-21</secondary_id>
    <nct_id>NCT01912469</nct_id>
  </id_info>
  <brief_title>Effects of Traumeel®S Tablets on Exercise Induced Muscle Damage and Muscle Soreness</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prof. Dr. med. Frank Christoph Mooren</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biologische Heilmittel Heel GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Giessen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Giessen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate and compare the effects of Traumeel®S tablets versus placebo on exercise
      induced muscle damage and muscle soreness for 72 hours after strenuous eccentric exercise
      test on downhill treadmill.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in post-exercise two baseline levels up to 72-hours of primary muscle damage marker creatine kinase (CK)</measure>
    <time_frame>72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in post-exercise two baseline levels up to 72-hours Short Form McGill Questionnaire total scores and separate VAS pain ratings</measure>
    <time_frame>72 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in post-exercise two baseline levels up to 72-hours of immunomodulators (35 lab parameters)</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in post-exercise two baseline levels up to 72-hours of immune status and activation markers (7 lab parameters)</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in post-exercise two baseline levels up to 72-hours of maximum isometric strength (thigh flexors and extensors)</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in post-exercise two baseline levels up to 72-hours of muscle marker Lactate Dehydrogenase</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Exercise-induced Muscle Soreness</condition>
  <arm_group>
    <arm_group_label>Traumeel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Traumeel tablets by mouth the total amount for 72 hours will be 26 tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The Placebo tablets (300 mg lactose monohydrate and 1,5 mg magnesium stearate) by mouth the total amount for 72 hours will be 26 tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Traumeel</intervention_name>
    <description>oral, Day 1: one tablet every 15 minutes for two hours after the exercise test, 6 hours and 10 hours after the exercise test; Day 2 and 3: two tablets thrice daily; Day 4: two tablets in the morning</description>
    <arm_group_label>Traumeel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral, Day 1: one tablet every 15 minutes for two hours after the exercise test, 6 hours and 10 hours after the exercise test; Day 2 and 3: two tablets thrice daily; Day 4: two tablets in the morning</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Sex: male

          -  Age ≥ 18 and ≤ 40 years

          -  BMI ≥ 18.5 and &lt; 27,5 kg/m2 (WHO standard for normal range BMI) [48]

          -  Maximum relative oxygen uptake (VO2max) &lt; 53 ml/kg x min

          -  General state of good health

          -  Non-smoker

          -  Medically approved unrestricted participation in sports as shown by diagnostic
             performance test conducted on treadmill no longer than 3 months prior to study entry

          -  Willingness to provide signed informed consent

        Exclusion Criteria:

          -  Regular eccentric exercise training

          -  Weekly training volume ≥ 6 hours

          -  Use of dietary supplements (incl. high-dosed vitamins and minerals)

          -  Chronic immune deficiency

          -  Current infection

          -  Heart and/or circulation disorders

          -  Abnormal findings on exercise ECG

          -  Musculoskeletal disorders

          -  Any current clinical condition that requires systemic treatment or might have an
             impact on study objectives

          -  Hypersensitivity to botanicals of the Compositae family (e.g. Echinacea)

          -  Lactose intolerance

          -  Illicit drug or alcohol abuse

          -  Participation in another clinical trial within 4 weeks prior to study entry
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank C. Mooren, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Sports Medicine, Institute of Sports Science, University of Giessen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Sports Medicine, Institute of Sports Science, University of Giessen</name>
      <address>
        <city>Giessen</city>
        <zip>35394</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 26, 2013</study_first_submitted>
  <study_first_submitted_qc>July 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2013</study_first_posted>
  <last_update_submitted>September 12, 2013</last_update_submitted>
  <last_update_submitted_qc>September 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Giessen</investigator_affiliation>
    <investigator_full_name>Prof. Dr. med. Frank Christoph Mooren</investigator_full_name>
    <investigator_title>Prof. Dr. med. Frank Christoph Mooren</investigator_title>
  </responsible_party>
  <keyword>Muscle</keyword>
  <keyword>exercise</keyword>
  <keyword>soreness</keyword>
  <keyword>Damage</keyword>
  <keyword>Traumeel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myalgia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

